A Randomised, Double Blind, Parallel Group, Phase II, Multicentre Study to Assess the Efficacy of ZD1839 (Iressa) 250 and 500mg/day in Patients with Advanced Non-Small Cell Lung Cancer who have failed one or two previous Chemotherapy Regimens; at least one having contained Platinum.
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
No locations available